IRIS
CASADEI GARDINI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.066
AS - Asia 5.879
NA - Nord America 4.988
SA - Sud America 1.466
AF - Africa 120
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 5
Totale 18.532
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.724
RU - Federazione Russa 3.614
SG - Singapore 2.141
CN - Cina 1.645
BR - Brasile 1.178
IT - Italia 691
HK - Hong Kong 670
VN - Vietnam 640
SE - Svezia 495
BD - Bangladesh 324
FR - Francia 296
RO - Romania 267
DE - Germania 200
GB - Regno Unito 148
CA - Canada 131
AR - Argentina 125
IN - India 117
MX - Messico 81
NL - Olanda 75
FI - Finlandia 56
ID - Indonesia 52
JP - Giappone 52
PL - Polonia 50
ZA - Sudafrica 50
AT - Austria 48
EC - Ecuador 45
TR - Turchia 35
ES - Italia 34
IQ - Iraq 34
CO - Colombia 30
VE - Venezuela 23
CL - Cile 21
MA - Marocco 20
LT - Lituania 18
PY - Paraguay 18
MY - Malesia 16
AE - Emirati Arabi Uniti 15
IE - Irlanda 14
PH - Filippine 14
UA - Ucraina 14
UZ - Uzbekistan 14
PK - Pakistan 13
SA - Arabia Saudita 13
EG - Egitto 12
DZ - Algeria 11
AZ - Azerbaigian 10
NI - Nicaragua 10
JM - Giamaica 9
NP - Nepal 9
UY - Uruguay 9
IR - Iran 8
BO - Bolivia 7
HN - Honduras 7
KE - Kenya 7
MD - Moldavia 7
PE - Perù 7
TW - Taiwan 7
BE - Belgio 6
BH - Bahrain 6
OM - Oman 6
AU - Australia 5
BA - Bosnia-Erzegovina 5
CH - Svizzera 5
CR - Costa Rica 5
IL - Israele 5
KZ - Kazakistan 5
TN - Tunisia 5
TT - Trinidad e Tobago 5
AO - Angola 4
EU - Europa 4
KG - Kirghizistan 4
KR - Corea 4
LB - Libano 4
BB - Barbados 3
BG - Bulgaria 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
HR - Croazia 3
JO - Giordania 3
PA - Panama 3
SI - Slovenia 3
SV - El Salvador 3
TH - Thailandia 3
A1 - Anonimo 2
AL - Albania 2
BY - Bielorussia 2
CG - Congo 2
CI - Costa d'Avorio 2
CY - Cipro 2
ET - Etiopia 2
GR - Grecia 2
KW - Kuwait 2
PS - Palestinian Territory 2
QA - Qatar 2
RS - Serbia 2
SR - Suriname 2
XK - ???statistics.table.value.countryCode.XK??? 2
BM - Bermuda 1
BW - Botswana 1
CM - Camerun 1
Totale 18.520
Salva come PNG Salva come JPEG
Città #
Dallas 1.545
Singapore 1.092
Moscow 767
Hong Kong 662
Ashburn 491
San Jose 437
New York 361
Beijing 303
Ho Chi Minh City 246
Shanghai 245
Lauterbourg 232
Hefei 220
Lawrence 149
Princeton 149
Los Angeles 147
Hanoi 123
Milan 120
São Paulo 99
Santa Clara 85
Rome 67
Orem 66
Boardman 56
Nuremberg 50
Montreal 47
London 43
Warsaw 43
Tokyo 42
Rio de Janeiro 40
Helsinki 39
Council Bluffs 38
Guangzhou 34
Munich 34
Da Nang 33
Mexico City 32
Poplar 32
Atlanta 31
Belo Horizonte 31
Denver 31
Stockholm 31
Brooklyn 30
Naples 30
Vienna 30
Houston 27
Cesano Boscone 26
Chennai 26
Chicago 26
Porto Alegre 26
Toronto 26
Johannesburg 25
Frankfurt am Main 24
Phoenix 24
Haiphong 23
Amsterdam 21
Biên Hòa 21
Manchester 21
Brasília 20
Guarulhos 20
Ankara 18
Curitiba 18
Mumbai 18
Shenzhen 18
Buffalo 17
Dhaka 16
Lappeenranta 16
Tianjin 15
Quito 14
Romagnano Sesia 14
Tashkent 14
Boston 13
New Delhi 13
Baghdad 12
Bologna 12
Charlotte 12
Dublin 12
Guayaquil 12
Hải Dương 12
Querétaro 12
San Francisco 12
Seattle 12
Brescia 11
Buenos Aires 11
Can Tho 11
Changsha 11
Philadelphia 11
Salvador 11
Thái Nguyên 11
Turin 11
Washington 11
Baku 10
Bari 10
Cape Town 10
Columbus 10
Monza 10
Recife 10
Secaucus 10
The Dalles 10
Thái Bình 10
Calgary 9
Campinas 9
Hanover 9
Totale 9.267
Salva come PNG Salva come JPEG
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 430
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 420
Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part I – Surgical treatments 411
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study 349
EUS-guided GastroEnterostomy for management of malignant Gastric Outlet Obstruction: a prospective cohort study with matched comparison with Enteral Stenting 153
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 132
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 131
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 128
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 127
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents 120
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 117
Combined hepatocellular-cholangiocarcinoma: morpho-molecular updates and considerations 116
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 115
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 115
Correction to: Prospective minimally invasive pancreatic resections from the IGOMIPS registry: a snapshot of daily practice in Italy on 1191 between 2019 and 2022 (Updates in Surgery, (2023), 75, 6, (1439-1456), 10.1007/s13304-023-01592-7) 114
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 112
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 112
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial 112
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 110
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 110
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 110
Comparing Liver Venous Deprivation and Portal Vein Embolization for Perihilar Cholangiocarcinoma: Is It Time to Shift the Focus to Hepatic Functional Reserve Rather than Hypertrophy? 109
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 108
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 107
Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments 107
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 105
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 103
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis 103
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients 103
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 100
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 100
Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and 99mTc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization 90Y PET/CT 99
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? 99
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 99
Retrospective Evaluation and Significance of Neutrophil-to-Lymphocyte Ratio Prior to and 1 month Following Microwave Ablation of Hepatocellular Carcinoma 98
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 98
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 98
1H-NMR based serum metabolomics highlights different specific biomarkers between early and advanced hepatocellular carcinoma stages 98
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 97
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 94
Hierarchically Positioning Laparoscopic Microwave Ablation in the Therapeutic Span of Early Hepatocellular Carcinoma: A Real-Life Comparative Analysis 94
Acute oxaliplatin-induced thrombotic thrombocytopenic purpura: A case report and results from a cytoflourimetric assay of platelet fibrinogen receptor 93
Defining and predicting textbook outcomes for perihilar cholangiocarcinoma: analysis of factors improving achievement of desired postoperative outcomes 91
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 91
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 90
Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities 90
Angiogenesis in biliary tract cancer: targeting and therapeutic potential 89
Long-term and short-term prognostic value of the prognostic nutritional index in cancer: a narrative review 88
Cholangiocarcinoma: new perspectives for new horizons 88
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma? 88
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 86
EUS-GUIDED GASTROENTEROSTOMY FOR MANAGEMENT OF MALIGNANT GASTRIC OUTLET OBSTRUCTION: A PROSPECTIVE SERIES FROM THE PROTECT REGISTRY 85
Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study 85
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 85
Mismatch repair deficiency as prognostic factor for stage III small bowel adenocarcinoma: A multicentric international study 84
Minimally Invasive Approach Provides Oncological Benefit in Patients with High Risk of Very Early Recurrence (VER) After Surgery for Intrahepatic Cholangiocarcinoma (iCCA) 84
A Clinicopathologic Comparison Between Early-Onset and Late-Onset Small Bowel Adenocarcinoma: A Multicenter International Study 84
Alpha-fetoprotein surge following high-dose chemotherapy in germ cell tumours 84
ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib 84
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 83
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 83
Correction: Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and 99mTc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization 90Y PET/CT 82
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 82
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 81
The role of anti-angiogenics in pre-treated metastatic BRAF-mutant colorectal cancer: A pooled analysis 81
The oncologic burden of residual disease in incidental gallbladder cancer: An elastic net regression model to profile high-risk features 80
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming 80
Sorafenib for the treatment of unresectable hepatocellular carcinoma: Preliminary toxicity and activity data in dogs 80
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 80
Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study 79
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 78
Over-the-Wire Lumen-Apposing Metal Stent Exchange for Management of a Long-Term Choledochoduodenostomy Dysfunction 77
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 75
BRAF-mutated colorectal cancer: Clinical and molecular insights 75
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 75
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting 74
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 74
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 73
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma 73
Treatment options for advanced hepatocellular carcinoma: the potential of biologics 73
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 72
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment 72
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 72
Platelets and hepatocellular cancer: Bridging the bench to the clinics 72
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 72
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 72
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience 71
Adjuvant chemotherapy after neoadjuvant chemo-radiotherapy and surgery in locally advanced rectal cancer. A systematic review of literature with a meta-analysis of randomized clinical trials 71
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 71
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 71
Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma: Ready for Prime Time? 71
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 70
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology 70
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease 70
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 69
Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study 69
Same-session endoscopic diagnosis and symptom palliation in pancreato-biliary malignancies: Clinical impact of rapid on-site evaluation (ROSE) 68
Assessing the impact of COVID-19 on liver cancer management (CERO-19) 67
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study 67
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study 66
Totale 10.273
Salva come PNG Salva come JPEG
Categoria #
all - tutte 97.208
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 97.208
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022100 0 0 0 40 2 5 15 22 6 2 0 8
2022/2023842 325 171 70 12 2 123 25 46 49 5 6 8
2023/2024673 35 18 58 54 33 226 75 47 0 11 30 86
2024/20253.046 349 70 73 33 67 254 687 289 397 281 193 353
2025/202614.229 935 1.392 1.551 1.888 1.027 433 958 947 3.362 601 613 522
Totale 19.020